Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer (Q46772110)

25 December 2017

title

Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer (English)

1 reference

25 December 2017

author name string

Matthew R Cooperberg

1

1 reference

25 December 2017

Shiro Hinotsu

2

1 reference

25 December 2017

Mikio Namiki

3

1 reference

25 December 2017

Peter R Carroll

4

1 reference

25 December 2017

Hideyuki Akaza

5

1 reference

25 December 2017

publication date

19 September 2014

1 reference

25 December 2017

published in

BJU International

1 reference

25 December 2017

volume

117

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

102-109

1 reference

25 December 2017

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

cites work

1 reference

Guideline for the management of clinically localized prostate cancer: 2007 update.

21 January 2018

1 reference

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

21 January 2018

1 reference

Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.

21 January 2018

1 reference

Time trends and local variation in primary treatment of localized prostate cancer

21 January 2018

1 reference

Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?

21 January 2018

1 reference

Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications

21 January 2018

1 reference

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry

21 January 2018

1 reference

Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.

21 January 2018

1 reference

Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy

21 January 2018

1 reference

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer

21 January 2018

1 reference

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

21 January 2018

1 reference

Survival following primary androgen deprivation therapy among men with localized prostate cancer

21 January 2018

1 reference

Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy

21 January 2018

1 reference

National practice patterns and time trends in androgen ablation for localized prostate cancer

21 January 2018

1 reference

Impact of age at diagnosis on prostate cancer treatment and survival

21 January 2018

1 reference

Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist

21 January 2018

1 reference

Reduction in physician reimbursement and use of hormone therapy in prostate cancer

21 January 2018

1 reference

Reimbursement policy and androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study

21 January 2018

1 reference

The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.

21 January 2018

1 reference

Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment

21 January 2018

1 reference

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients

21 January 2018

1 reference

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival

21 January 2018

1 reference

Intermittent versus continuous androgen deprivation in prostate cancer

21 January 2018

1 reference

Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004.

21 January 2018

1 reference

21 January 2018

Global cancer statistics

1 reference

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJU.12937

1 reference

25 December 2017

1 reference

25 December 2017